VIVES is a multi-sector fund that invests in projects with a positive societal impact
Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models.
With the...
Axinesis is a spin-off of the Université catholique de Louvain (Belgium), which has a clear mission: to improve the functional recovery of patients through innovative and accessible technologies...
Emolytics is a spin-off company of UCLouvain (Belgium) which is closely supported by the Louvain Technology Transfer Office. The technology originated in the University's research center in 2009 as a...
Vincent Mouret, Chairman of the board of Cissoid :
"As Chairman of the board of Cissoid, I’ve been working closely to VIVES for the last 10 years.
I have really appreciated VIVES involvement and...
Chris Buyse, Co founder and Managing Partner of Fund+ :
"Fund+ is impressed by the outstanding scientific achievements of our Belgian universities and therefore supports and invests in its innovative...
David Frenay, CEO Emolytics :
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
LMO (Luxembourg & UK) and In-Space Missions Ltd (UK) have partnered to explore the use of small satellite platforms for space-based Space Domain Awareness (SDA) as part of LMO’s AUREA (Autonomous
New funding will support the rapid growth of Aphea.Bio, solidifying its position as a frontrunner in biological product development for agriculture.
Gent, Belgium, 11 July 2023 – Aphea.Bio, a Belgium